Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SL800P is a pseudogene derived from the 7SL RNA, which is the RNA component of the signal recognition particle (SRP), but RN7SL800P itself is not a protein-coding gene nor a typical therapeutic target[4][5][6]. It is a human genomic pseudogene representing a noncoding RNA sequence similar to 7SL RNA, the RNA component of the signal recognition particle (SRP)[4][5][6]. While functional 7SL RNA is essential for cotranslational protein targeting to the endoplasmic reticulum[1][3], RN7SL800P itself is a pseudogene—a truncated, non-functional copy likely generated by retrotransposition, characterized by its incapacity to encode RNA functional in the SRP complex[5][6]. Most 7SL RNA pseudogenes do not produce transcripts or proteins and are not considered therapeutic targets, biomarkers, or direct disease agents[5][6]. Due to the nature of pseudogenes, RN7SL800P does not mediate biological functions, interact with drugs, or serve as a biomarker. Moreover, there is no evidence supporting its use as a pharmacological or diagnostic target.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, 7SL, cytoplasmic 800, pseudogene (RN7SL800P).